Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Today’s radar is not built around one single theme. It is built around three very different biotech catalyst profiles: a small-cap GLP-1 implant narrative, a cleaner late-stage rare-disease regulatory story, and a highly speculative oncology microcap with a real but very early dosing question.
Deep dive on Trump Media ($DJT) after Q1 2026: $871K revenue, -$405.9M net loss driven by crypto marks, 9,542 BTC treasury, the CEO change, the paused Truth Social spin-off and the pending ~$6B TAE Technologies fusion merger.
Deep dive on the July 2026 AI infrastructure trade: TeraWulf's $19B Anthropic data-center lease, Broadcom's Apple custom-chip extension through 2031, and Micron's AI-driven memory super-cycle. $WULF, $AVGO, $MU.
Deep dive on Uranium Energy Corp. ($UEC): fiscal Q3 2026, U.S. ISR restart at Christensen Ranch and Burke Hollow, 1.456M lbs uranium inventory, $794M liquidity, no debt, Roughrider, UR&C conversion, catalysts and risks.
Deep dive on Lithium Americas ($LAC): Thacker Pass Phase 1 construction after Q1 2026, ~$1.2B cash, $2.93B capex, GM/DOE funding, dilution, lithium market risks, catalysts and red flags.
Biotech radar for July 6, 2026: Pharvaris ($PHVS) FDA NDA acceptance with an April 2027 PDUFA date, Agenus ($AGEN) three-year BOT+BAL survival data in MSS colorectal cancer, and Ionis ($IONS) Phase 3 pivotal enrollment complete in Angelman syndrome.
70+ biotech, small-cap, FDA and trading terms explained clearly: PDUFA date, CRL, cash runway, short squeeze, surrogate endpoint and more.
The cannabis trade is not waiting for a simple headline. It is watching an administrative record being built in real time. The key question is not only whether marijuana can move from Schedule I to Schedule III, but whether the evidence supporting that move is strong enough to survive opposition, procedural scrutiny and possible litigation.
Critical Metals Corp. ($CRML) is the starting point, but the full map reaches across MP Materials ($MP), USA Rare Earth ($USAR), Energy Fuels ($UUUU), NioCorp ($NB), Lithium Americas ($LAC), Albemarle ($ALB), Sigma Lithium ($SGML), Nouveau Monde Graphite ($NMG) and Westwater Resources ($WWR): heavy rare earths, lithium, graphite, niobium, scandium, magnet manufacturing, defense procurement, EV motors, wind turbines, robotics, electronics and the geopolitical race to rebuild strategic supply chains outside China.
Insider trading this week (June 29-July 3, 2026): the 20 biggest buys and 20 biggest sells by dollar value, with names, tickers, amounts and next catalysts.
Ten artificial-intelligence names, screened for momentum, chart position and base, with the genuine small/mid caps up top. For each one: a mini chart, a short explainer, the AI niche and the real analyst price targets with sources.
Watchlist 2026 · Defense & Defense-Tech Drones Space Counter-UAS Momentum AVAV · KTOS · RKLB · LUNR · PL · DRS · KRMN · RCAT · UMAC · ONDS Defense: the 10 hottest stocks of July 2026 Ten small and…
The junior developer aiming to bring the Neves hard-rock lithium project into production in Minas Gerais' "Lithium Valley": a fully paid processing plant already shipped to Brazil, offtake deals with Mitsui, Chengxin and Yahua — but also years of delays, heavy dilution and a CEO who controls 51% of the vote.
The microreactor developer aiming to become a fully integrated nuclear supply chain for the AI data-center era: pre-commercial technology, a large cash pile and a calendar of regulatory and test milestones.
MicroVision’s new Southeast Asia partnership adds another piece to a busy 2026 commercial reset, but the story remains a high-risk execution trade: stronger customer activity, broader LiDAR portfolio, still-small revenue, meaningful cash burn and visible financing risk.
Today’s biotech tape is not built around one single mega-cap headline. It is a classic catalyst radar session: one small oncology name with a fresh Phase 2a survival signal, one late-stage inflammatory disease story with a major Phase 3/NDA setup but financing pressure, one infectious-disease micro-cap tied to babesiosis development, and one diabetes medtech name moving from clearance into real-world use.
Abivax has moved from a speculative French biotech story to one of the most closely watched late-stage ulcerative colitis names in global healthcare. The June 29 ABTECT Maintenance Part 2 update did not simply add another dataset. It directly addressed the safety debate that had pressured the stock after the June 1 maintenance readout and pushed investors to reassess the risk/reward profile ahead of the planned U.S. NDA submission in Q4 2026.
Deep Dive · Defense Autonomy · $VWAV VisionWave Holdings (Nasdaq: $VWAV): Meteor Aerospace Deal Turns the Pre-Market Spike Into a Real Defense-Autonomy Test VisionWave announced a definitive binding agreement to acquire a 51% controlling interest in Meteor Aerospace, an Israeli…
The market did not get a final ruling today. What it got is the start of a federal process that could decide whether the cannabis trade remains a narrow medical-only tax story or becomes a broader sector repricing catalyst.
A deeper, U.S.-focused Merlintrader editorial on how to read sell-side price targets in small and mid-cap biotech, why 12-month targets often fail as forecasts, and why binary events such as PDUFA dates, Phase 3 readouts and FDA advisory committees can turn the “average target” into a misleading comfort number.